Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696017 | 1.00 | CTSS (0.79) | CTSSCTSL | |
| SCHEMBL696309 | 1.00 | CTSS (0.79) | CTSSCTSL | |
| SCHEMBL694939 | 0.92 | CTSS (0.75) | CTSSCTSL | |
| SCHEMBL695124 | 0.92 | CTSS (0.75) | CTSSCTSL | |
| SCHEMBL695660 | 0.91 | CTSS (0.73) | CTSSCTSL | |
| SCHEMBL694842 | 0.90 | CTSS (0.72) | CTSSCTSL | |
| SCHEMBL695991 | 0.90 | CTSS (0.72) | CTSSCTSL | |
| SCHEMBL695314 | 0.90 | CTSS (0.73) | CTSSCTSL | |
| SCHEMBL695546 | 0.90 | CTSS (0.73) | CTSSCTSL | |
| SCHEMBL15327170 | 0.89 | CTSS (0.64) | CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | claimed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| EP-2776392-B1 | PROCESS FOR THE PREPARATION OF 1-ACYL-4-PHENYLSULFONYLPROLINAMIDE DERIVATIVES AND NEW INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2016-05-18 | — | — | EP | disclosed |
| US-8796471-B2 | Process for the preparation of proline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796471-B2 | Process for the preparation of proline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130123512-A1 | PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123512-A1 | PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123512-A1 | PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES | CTSS, CTSV, CTSZ | CTSS 1/4885CTSL 9/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | CTSS 1542/4885CTSL 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.